Genentech culls muscle-preserving drug in genetic diseases, raising questions about obesity trialnews2026-03-20T10:42:18+00:00March 20th, 2026|Endpoints News|
AstraZeneca deepens UK-China ties with cell therapy R&D hub, manufacturing plansnews2026-03-19T15:29:18+00:00March 19th, 2026|Endpoints News|
Pfizer seeks earlier use of Talzenna in prostate cancer with Phase 3 winnews2026-03-19T14:24:11+00:00March 19th, 2026|Endpoints News|
Updated: Lilly’s triple-G comparable with Mounjaro, first Phase 3 diabetes data suggestnews2026-03-19T10:45:27+00:00March 19th, 2026|Endpoints News|
Xaira unveils AI model X-Cell for predicting virtual cellsnews2026-03-18T10:00:04+00:00March 18th, 2026|Endpoints News|
Rhythm’s Imcivree fails Phase 3 rare form obesity trialnews2026-03-17T13:48:31+00:00March 17th, 2026|Endpoints News|
Bicycle to cut 30% of staff after cancer drug’s regulatory setbacknews2026-03-17T13:32:34+00:00March 17th, 2026|Endpoints News|
Roche, Nvidia to build largest ‘AI factory’ in pharmanews2026-03-17T11:30:11+00:00March 17th, 2026|Endpoints News|
J&J pulls out of NYC biotech incubator as it shrinks locationsnews2026-03-17T11:00:29+00:00March 17th, 2026|Endpoints News|
China mRNA therapy startup Innorna to test gout treatment in USnews2026-03-17T11:00:08+00:00March 17th, 2026|Endpoints News|
